The Latin America, Middle East and Africa In Situ Hybridization Market would witness market growth of 10.3% CAGR during the forecast period (2022-2028).
The fundamentals of nucleic acid hybridization that underpin Southern blotting and in situ hybridization are the same. Using a complementary, labeled nucleic acid probe, mRNA signals may be found in tissues that have been appropriately maintained.
Due to the thermodynamic stability of RNA-RNA duplexes, single-stranded RNA probes (riboprobes) are typically preferred. The methodology has been used on various Populus, Eucalyptus, and Pinus tissues. It may be modified further with different labeling and detection techniques or extended to additional species/tissues.
Saudi Arabia mostly finances healthcare spending in the Gulf Cooperation Council (GCC), and the Saudi government continues to place a high premium on the industry. The Saudi Arabian government has budgeted about $65 billion to develop the healthcare system as part of Vision 2030. Additionally, it wants to privatize 290 hospitals and 2,300 primary health clinics by 2030, increasing private sector participation from 40% to 65%. Due to the region's increasing healthcare infrastructure, vendors in the in-situ hybridization market would have many possibilities to invest in the LAMEA area.
The Brazil market dominated the LAMEA In Situ Hybridization Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $28.8 million by 2028.The Argentina market is experiencing a CAGR of 10.9% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 10% during (2022 - 2028).
Based on Technology, the market is segmented into Fluorescent In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH). Based on End Use, the market is segmented into Research & Diagnostic Laboratories, Academic Institutes, CROs and Others. Based on Application, the market is segmented into Cancer, Cytogenetics, Developmental Biology, Infectious Diseases and Others. Based on Product, the market is segmented into Instruments, Kits & Probes, Software and Services. Based on Probe, the market is segmented into DNA and RNA. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abbott Laboratories, PerkinElmer, Inc., Agilent Technologies, Inc., Merck Group, Bio-Rad Laboratories, Inc., Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.), Danaher Corporation (Leica Biosystems), F. Hoffmann-La Roche Ltd., and Neogenomics, Inc.
The fundamentals of nucleic acid hybridization that underpin Southern blotting and in situ hybridization are the same. Using a complementary, labeled nucleic acid probe, mRNA signals may be found in tissues that have been appropriately maintained.
Due to the thermodynamic stability of RNA-RNA duplexes, single-stranded RNA probes (riboprobes) are typically preferred. The methodology has been used on various Populus, Eucalyptus, and Pinus tissues. It may be modified further with different labeling and detection techniques or extended to additional species/tissues.
Saudi Arabia mostly finances healthcare spending in the Gulf Cooperation Council (GCC), and the Saudi government continues to place a high premium on the industry. The Saudi Arabian government has budgeted about $65 billion to develop the healthcare system as part of Vision 2030. Additionally, it wants to privatize 290 hospitals and 2,300 primary health clinics by 2030, increasing private sector participation from 40% to 65%. Due to the region's increasing healthcare infrastructure, vendors in the in-situ hybridization market would have many possibilities to invest in the LAMEA area.
The Brazil market dominated the LAMEA In Situ Hybridization Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $28.8 million by 2028.The Argentina market is experiencing a CAGR of 10.9% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 10% during (2022 - 2028).
Based on Technology, the market is segmented into Fluorescent In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH). Based on End Use, the market is segmented into Research & Diagnostic Laboratories, Academic Institutes, CROs and Others. Based on Application, the market is segmented into Cancer, Cytogenetics, Developmental Biology, Infectious Diseases and Others. Based on Product, the market is segmented into Instruments, Kits & Probes, Software and Services. Based on Probe, the market is segmented into DNA and RNA. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abbott Laboratories, PerkinElmer, Inc., Agilent Technologies, Inc., Merck Group, Bio-Rad Laboratories, Inc., Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.), Danaher Corporation (Leica Biosystems), F. Hoffmann-La Roche Ltd., and Neogenomics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Technology
- Fluorescent In Situ Hybridization (FISH)
- Chromogenic In Situ Hybridization (CISH)
By End Use
- Research & Diagnostic Laboratories
- Academic Institutes
- CROs
- Others
By Application
- Cancer
- Cytogenetics
- Developmental Biology
- Infectious Diseases
- Others
By Product
- Instruments
- Kits & Probes
- Software
- Services
By Probe
- DNA
- RNA
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc
- Abbott Laboratories
- PerkinElmer, Inc
- Agilent Technologies, Inc
- Merck Group
- Bio-Rad Laboratories, Inc
- Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
- Danaher Corporation (Leica Biosystems)
- F. Hoffmann-La Roche Ltd
- Neogenomics, Inc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA In Situ Hybridization Market, by Technology
1.4.2 LAMEA In Situ Hybridization Market, by End Use
1.4.3 LAMEA In Situ Hybridization Market, by Application
1.4.4 LAMEA In Situ Hybridization Market, by Product
1.4.5 LAMEA In Situ Hybridization Market, by Probe
1.4.6 LAMEA In Situ Hybridization Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. LAMEA In Situ Hybridization Market by Technology
3.1 LAMEA Fluorescent In Situ Hybridization (FISH) Market by Country
3.2 LAMEA Chromogenic In Situ Hybridization (CISH) Market by Country
Chapter 4. LAMEA In Situ Hybridization Market by End-use
4.1 LAMEA Research & Diagnostic Laboratories Market by Country
4.2 LAMEA Academic Institutes Market by Country
4.3 LAMEA CROs Market by Country
4.4 LAMEA Others Market by Country
Chapter 5. LAMEA In Situ Hybridization Market by Application
5.1 LAMEA Cancer Market by Country
5.2 LAMEA Cytogenetics Market by Country
5.3 LAMEA Developmental Biology Market by Country
5.4 LAMEA Infectious Diseases Market by Country
5.5 LAMEA Others Market by Country
Chapter 6. LAMEA In Situ Hybridization Market by Product
6.1 LAMEA Instruments Market by Country
6.2 LAMEA Kits & Probes Market by Country
6.3 LAMEA Software Market by Country
6.4 LAMEA Services Market by Country
Chapter 7. LAMEA In Situ Hybridization Market by Probe
7.1 LAMEA DNA Market by Country
7.2 LAMEA RNA Market by Country
Chapter 8. LAMEA In Situ Hybridization Market by Country
8.1 Brazil In Situ Hybridization Market
8.1.1 Brazil In Situ Hybridization Market by Technology
8.1.2 Brazil In Situ Hybridization Market by End-use
8.1.3 Brazil In Situ Hybridization Market by Application
8.1.4 Brazil In Situ Hybridization Market by Product
8.1.5 Brazil In Situ Hybridization Market by Probe
8.2 Argentina In Situ Hybridization Market
8.2.1 Argentina In Situ Hybridization Market by Technology
8.2.2 Argentina In Situ Hybridization Market by End-use
8.2.3 Argentina In Situ Hybridization Market by Application
8.2.4 Argentina In Situ Hybridization Market by Product
8.2.5 Argentina In Situ Hybridization Market by Probe
8.3 UAE In Situ Hybridization Market
8.3.1 UAE In Situ Hybridization Market by Technology
8.3.2 UAE In Situ Hybridization Market by End-use
8.3.3 UAE In Situ Hybridization Market by Application
8.3.4 UAE In Situ Hybridization Market by Product
8.3.5 UAE In Situ Hybridization Market by Probe
8.4 Saudi Arabia In Situ Hybridization Market
8.4.1 Saudi Arabia In Situ Hybridization Market by Technology
8.4.2 Saudi Arabia In Situ Hybridization Market by End-use
8.4.3 Saudi Arabia In Situ Hybridization Market by Application
8.4.4 Saudi Arabia In Situ Hybridization Market by Product
8.4.5 Saudi Arabia In Situ Hybridization Market by Probe
8.5 South Africa In Situ Hybridization Market
8.5.1 South Africa In Situ Hybridization Market by Technology
8.5.2 South Africa In Situ Hybridization Market by End-use
8.5.3 South Africa In Situ Hybridization Market by Application
8.5.4 South Africa In Situ Hybridization Market by Product
8.5.5 South Africa In Situ Hybridization Market by Probe
8.6 Nigeria In Situ Hybridization Market
8.6.1 Nigeria In Situ Hybridization Market by Technology
8.6.2 Nigeria In Situ Hybridization Market by End-use
8.6.3 Nigeria In Situ Hybridization Market by Application
8.6.4 Nigeria In Situ Hybridization Market by Product
8.6.5 Nigeria In Situ Hybridization Market by Probe
8.7 Rest of LAMEA In Situ Hybridization Market
8.7.1 Rest of LAMEA In Situ Hybridization Market by Technology
8.7.2 Rest of LAMEA In Situ Hybridization Market by End-use
8.7.3 Rest of LAMEA In Situ Hybridization Market by Application
8.7.4 Rest of LAMEA In Situ Hybridization Market by Product
8.7.5 Rest of LAMEA In Situ Hybridization Market by Probe
Chapter 9. Company Profiles
9.1 Thermo Fisher Scientific, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.2 Abbott Laboratories
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 PerkinElmer, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.4 Agilent Technologies, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.5 Merck Group
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.6 Bio-Rad laboratories, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expenses
9.7 Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.8 Danaher Corporation (Leica Biosystems)
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.9 F. Hoffmann-La Roche Ltd.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.10. Neogenomics, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental Analysis
9.10.4 Research & Development Expenses
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Abbott Laboratories
- PerkinElmer, Inc.
- Agilent Technologies, Inc.
- Merck Group
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
- Danaher Corporation (Leica Biosystems)
- F. Hoffmann-La Roche Ltd.
- Neogenomics, Inc.
Methodology
LOADING...
